The Phase 2b COPERNICUS Study of Subcutaneous Amivantamab with Lazertinib as First-Line Treatment, or with Chemotherapy as Second-Line Treatment, for EGFR-Mutated Non-Small Cell Lung Cancer: a Vodcast
一项针对EGFR突变型非小细胞肺癌患者的IIb期COPERNICUS研究：皮下注射阿米伐他单抗联合拉泽替尼作为一线治疗，或联合化疗作为二线治疗。视频播客：
期刊:Oncology and Therapy
影响因子:3.2
doi:10.1007/s40487-025-00386-8
Halmos, Balazs; Florez, Narjust; Goldberg, Sarah; Iams, Wade; Le, Xiuning; Leal, Ticiana; Nguyen, Danny; Raez, Luis E; Riess, Jonathan W; Sabari, Joshua; Bjork, David; Stigger, Nichelle; Xia, Yichuan; Cifuentes, Paul; D'Andrea, Denise; Shanoon, Farah; Johnson, Andy L; Johnson, Melissa L
